Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
VentriPoint Diagnostics ( (TSE:VPT) ) just unveiled an update.
Ventripoint Diagnostics Ltd. has successfully closed a $500,000 non-brokered private placement of convertible debenture units, pending final approval from the TSXV Venture Exchange. The funds raised will be used to support the company’s operational costs, including sales and marketing, hiring additional key personnel, and general working capital, potentially enhancing its market position and operational capabilities.
More about VentriPoint Diagnostics
Ventripoint Diagnostics Ltd. is an industry leader in applying AI to echocardiography, offering VMS+ products that provide accurate volumetric cardiac measurements equivalent to MRI. Their technology is versatile, compatible with all ultrasound systems, and supported by regulatory approvals in the U.S., Europe, and Canada.
YTD Price Performance: 45.83%
Average Trading Volume: 266,810
Technical Sentiment Consensus Rating: Hold
Current Market Cap: C$30.12M
See more insights into VPT stock on TipRanks’ Stock Analysis page.